보고서 요약(국문)

시장 개요
전 세계 고환암 시장은 2022년 8억 1,130만 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 5.6%의 성장률을 보이며 2030년에는 12억 4,630만 달러에 이를 것으로 예상됩니다. 특정 유전적 구성에 대한 이해도 향상을 통한 개인 맞춤형 의학으로의 전환과 같은 추세가 전 세계 고환암 시장 성장을 주도할 것으로 전망됩니다.
전 세계 고환암 시장은 최근 몇 년간 크게 성장했으며, 이러한 상승세는 지속될 것으로 예상됩니다. 표적 치료 및 새로운 면역 요법 옵션의 등장과 같은 여러 중요한 추세에 힘입어 시장은 전환기를 맞고 있습니다.
또한, 고환암 발병률 증가, 진단 기술 발전, 인식 개선 및 검진 프로그램 확대, 그리고 치료법의 발전이 고환암 시장 규모 확대를 견인하고 있습니다. 임상 시험 건수 증가로 새로운 치료법 개발이 활발해지면서 북미 지역에서 수요가 증가하고 있으며, 화이자(Pfizer Inc.), 프레제니우스 카비(Fresenius Kabi AG) 등 주요 경쟁 업체들이 시장에서 활발하게 활동하고 있습니다.
시장 동향
고환암 진단 증가가 고환암 시장 성장을 견인
전 세계 고환암 시장은 전 세계적으로 고환암 진단 건수가 증가함에 따라 빠르게 성장하고 있습니다. 예를 들어, 미국 임상종양학회(ASCO)의 2023년 보고서에 따르면 미국에서 9,190명, 전 세계적으로 74,458명이 고환암 진단을 받을 것으로 예상됩니다. 특히 고환암은 20~34세 남성에게 가장 흔하게 진단되는 악성 종양이며, 20~29세와 30~39세 남성에서도 발병 사례가 증가하고 있습니다.
이러한 추세는 인식 개선과 검진 프로그램 확대로 이어져 조기 발견과 생존율 향상을 가져왔습니다. 환자의 변화하는 요구를 충족하기 위해 지속적인 연구 개발 활동은 표적 치료제, 면역 치료제 및 맞춤형 의약품 개발에 집중되고 있습니다. 따라서 암 진단 증가로 인해 시장은 예측 기간 동안 성장할 것으로 예상됩니다.
새로운 치료 옵션 개발이 시장 성장을 견인할 것입니다.
새로운 치료 옵션의 사용이 시장을 주도할 것으로 예상됩니다. 이는 화학 요법과 같은 기존 치료법에 대한 내성 발생 및 유전자 치료의 발전과 같은 요인 때문입니다. 예를 들어, 2023년 4월 본 대학 병원(UKB)의 연구진은 시스플라틴 내성 고환암 환자를 위한 잠재적으로 혁신적인 치료법을 발견했습니다. 연구진은 CRISPR 유전자 가위를 사용하여 고환암 세포에서 시스플라틴 내성의 핵심 조절자인 NAE1 유전자를 발견했습니다.
NAE1 억제제인 MLN4924는 시스플라틴의 효능을 회복시켰을 뿐만 아니라 종양 세포 사멸을 증가시켰습니다. 이러한 연구 결과는 고환암 환자의 시스플라틴 내성을 해결할 수 있는 새롭고 더 효과적인 약물의 가능성을 제시하며, 잠재적으로 치료 결과를 향상시킬 수 있습니다. 따라서 고환암 치료 옵션의 발전은 향후 시장 성장을 견인할 것으로 예상됩니다.
고환암 치료와 관련된 부작용은 시장 성장을 저해할 수 있습니다.
고환암 시장은 항암제 부작용과 조기 진단 부족 등의 요인으로 인해 성장을 저해할 것으로 예상됩니다. 화학 요법은 효과적이지만 피로, 메스꺼움, 구토, 저림, 따끔거림, 청력 손실, 이명 등의 부작용을 유발할 수 있으며 심각한 감염 위험을 증가시킬 수 있습니다.
예를 들어, 블레오마이신은 심각한 폐 염증을 유발하는 것으로 알려져 있어 의료진에게 즉시 증상을 알려야 합니다. 또한 고환암 치료를 받는 사람들은 혈전이 발생하기 쉽습니다.
세분화 분석
세계 고환암 시장은 유형, 병기, 약물 종류, 치료법, 유통 채널 및 지역별로 세분화됩니다.

수술 부문은 우수한 효과 덕분에 고환암 시장 점유율의 약 34.6%를 차지했습니다.
수술 부문은 효과성, 기술 발전, 그리고 고환암 완치율 향상으로 인해 고환암의 1차 치료법이자 선호되는 치료법으로 자리매김하고 있어 고환암 시장을 주도할 것으로 예상됩니다. 수술은 복막 뒤쪽의 림프절(후복막)을 제거하는 고환암의 주요 치료법입니다.
또한, 근치적 서혜부 고환절제술은 세미노마 및 비세미노마 고환암 모두의 치료에 사용됩니다. 더 나아가, 최소 침습 수술과 같은 기술 발전이 시장 성장을 견인하고 있습니다.
예를 들어, 마운트 시나이 병원은 로봇 보조 후복막 림프절 절제술(R-RPLND)을 시행했습니다. R-RPLND는 개복 후복막 림프절 절제술보다 침습성이 낮은 새로운 고환암 수술법입니다. 이 수술은 복막후강에 있는 종양을 제거하기 위해 다섯 개의 작은 절개를 하는 방식으로 진행되어 환자의 회복 속도를 높입니다. 따라서 수술 치료의 발전으로 인해 이 분야는 예측 기간 동안 시장을 주도할 것으로 예상됩니다.
지역별 시장 점유율
북미는 임상 시험 증가에 힘입어 2022년 시장 점유율의 약 40.7%를 차지했습니다.
북미, 특히 미국은 기존 시장 참여 기업들의 존재와 새로운 치료법 개발을 위한 기업들의 투자 증가로 인해 전 세계 고환암 시장을 주도하고 있습니다. 또한, 임상 시험의 증가로 환자 예후 개선을 위한 새로운 치료법이 개발되고 있습니다.
예를 들어, UNC 라인버거 종합 암 센터는 라인버거 종합 암 센터의 대학 암 연구 기금과 협력하여 2022년부터 임상 시험을 진행하고 있습니다. 이 시험은 비정자세포종양(NSGCT)을 가진 성인을 대상으로 하는 2상 임상 시험입니다. 본 연구의 목적은 변형 T세포의 저장소를 구축하고 대상자의 혈장 또는 종양에서 변형 T세포의 존재를 확인하는 것입니다. 수집된 생체 시료(종양 조직, 혈액, 변형 T세포 포함)는 체내 및 종양 내 변형 T세포의 존재 및 수명에 대해 더 자세히 알아보는 데 사용될 것입니다.
또한, 본 연구는 항체와 T세포라는 두 가지 서로 다른 질병 치료 방식을 결합하여 미래의 암 치료법을 발전시키는 것을 목표로 합니다. 이 연구는 이전 ATLCAR 투여 시험에서 얻은 안전성 및 효능 데이터를 기반으로 합니다. CD30은 CD30 항원에 특이적인 자가 T 림프구 키메라 항원 수용체 세포를 환자에게 투여하는 치료법이며, 임상 시험은 2026년 12월에 완료될 예정입니다.
경쟁 환경
고환암 시장의 주요 글로벌 기업으로는 Pfizer Inc., Fresenius Kabi AG, Abbott, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Xediton Pharmaceuticals, Accord Healthcare Limited, Baxter Healthcare Corporation, Sandoz International GmbH 및 Hikma Pharmaceuticals PLC가 있습니다. 그 외에도 여러 요인이 있습니다.

COVID-19 영향 분석
COVID-19 팬데믹은 특히 남성 생식 건강 측면에서 고환암 시장에 영향을 미칠 수 있습니다. 남성이 COVID-19에 더 취약하기 때문에 연구자들은 바이러스가 고환 기능에 영향을 미치는지, 정액에 바이러스가 존재하는지 여부를 조사해 왔습니다. COVID-19 감염 후 정액 매개변수의 변화, 호르몬 축의 변화, 생식세포 기능 장애가 나타났다는 연구 결과가 있습니다.
사후 고환 조직에서 바이러스 단백질이 확인된 것은 COVID-19 관련 고환 손상 가능성을 뒷받침합니다. 또한, SARS-CoV-2 감염은 염증 매개체에 영향을 미쳐 고환 손상을 유발하고 불임 위험을 높일 수 있습니다. 이러한 연구 결과는 COVID-19가 남성 생식 건강에 미치는 장기적인 영향과 고환암 시장에 미칠 수 있는 잠재적 영향에 대한 추가 연구의 중요성을 시사합니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 분쟁은 전 세계 고환암 시장에 영향을 미치고 있습니다. 우크라이나 내전으로 의료 서비스 접근성이 저하되면서 고환암 환자들이 필수적인 치료를 받기가 더욱 어려워졌습니다. 치료비 부담 증가와 경제 불안정으로 환자들의 재정적 부담이 가중되면서 의료 서비스 이용이 더욱 어려워졌습니다. 또한, 내전으로 인해 의료 지원을 꺼리는 사람들이 많아 진단과 치료가 지연되는 사례도 발생하고 있습니다.
이러한 장애물들은 전 세계 고환암 시장에 부정적인 영향을 미쳐 예상보다 더딘 성장을 초래했습니다. 하지만 우크라이나에서 보다 효과적인 치료법 개발과 고환암 인식 제고에 더욱 집중한다면 시장 성장 잠재력은 여전히 존재합니다. 전쟁이 종식되고 의료 서비스 접근성이 개선됨에 따라 시장은 회복될 것으로 예상됩니다. 그럼에도 불구하고 내전이 시장에 미치는 영향은 여전히 막대하며, 내전으로 인한 문제점과 기회를 해결하기 위한 지속적인 노력이 필요합니다.

유형별
• 생식세포 종양
o 세미노마
• 고전적 세미노마
• 정세포 세미노마
o 비세미노마
• 배아암
• 난황낭암
• 융모암
• 기형종
• 간질 종양
o 라이디히 세포 종양
o 세르톨리 세포 종양
• 기타
병기별
• 0기
• 1기
• 2기
• 3기
약물 계열별
• 알킬화제
• 토포이소머라제 II 억제제
• 글리코펩타이드 항생제
• 항미세소관제
• 기타
치료법별
• 수술
• 방사선 치료
• 화학 요법
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 2022년 6월 23일, 바이오엔텍(BioNTech SE)은 유럽의약품청(EMA)이 자사의 완전 소유 신약 후보 물질인 BNT211을 고환 생식세포 종양의 3차 또는 그 이후 치료제로 우선 심사 대상 의약품(PRIME)으로 지정했다고 발표했습니다. BNT211은 자사의 두 가지 독점 약물, 즉 종양태아 항원 클라우딘-6(CLDN6)을 표적으로 하는 자가 키메라 항원 수용체(CAR) T 세포 치료제와 CLDN6를 코딩하는 CAR-T 세포 증폭 RNA 백신(CARVac)을 결합한 최초의 혁신적인 치료법이 될 가능성이 있습니다.

• 2023년 6월 2일, 미국 식품의약국(FDA)은 중국 제약회사 치루제약(Qilu Pharmaceutical)과 협력하여 현재 공급 부족 상태인 항암제 시스플라틴의 공급량을 늘리기로 했습니다. 캐나다 제약회사 아포텍스(Apotex)는 50mg 바이알 형태의 주사제 시스플라틴을 임시로 공급할 예정입니다. 시스플라틴은 고환암 치료 시 90% 이상의 완치율을 보이며, 방광암, 자궁경부암, 난소암, 폐암, 위암, 유방암, 두경부암 치료에도 사용됩니다.

보고서 구매 이유:

• 유형, 병기, 약물 종류, 치료법, 유통 채널 및 지역별 글로벌 고환암 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

• 시장 동향 및 공동 개발 분석을 통해 사업 기회를 발굴할 수 있습니다.

• 모든 세그먼트를 포함한 고환암 시장 수준의 다양한 데이터가 담긴 엑셀 파일 제공.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석 자료가 담긴 PDF 보고서 제공.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료가 엑셀 파일로 제공됩니다.
글로벌 고환암 시장 보고서는 약 53개의 표, 54개의 그림, 그리고 195페이지 분량으로 구성될 예정입니다.
2023년 주요 독자층
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
Global Testicular Cancer Market reached US$ 811.3 million in 2022 and is expected to reach US$ 1,246.3 million by 2030 growing with a CAGR of 5.6% during the forecast period 2023-2030. The trend such as the shift towards personalized medicine by better understanding of specific genetic makeup is expected to dominate the global testicular cancer market.
The global testicular cancer market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as the usage of targeted therapies, and emerging immunotherapy options.
Furthermore, the rising prevalence of testicular cancer, advancements in diagnostic technologies, increasing awareness and screening programs, and advancements in treatment options for the disease are driving up the testicular cancer market size. The rising number of clinical trials has resulted in the development of novel treatments is seeing an increase in demand from North American regions with significant competitors like Pfizer Inc., Fresenius Kabi AG, and others actively operating in the market.
Market Dynamics
The Increasing Diagnosis of Testicular Cancer to Drive the Growth of the Testicular Cancer Market
The global testicular cancer market is growing rapidly, owing mainly due an increase in testicular cancer diagnoses worldwide. For instance, according to the American Society of Clinical Oncology (ASCO) report of 2023, testicular cancer will be diagnosed in 9,190 people in the U.S. and 74,458 people globally. Particularly, testicular cancer is the most commonly diagnosed malignancy in men aged 20 to 34, with a growing number of cases observed among men aged between 20 to 29 and 30 to 39.
This trend has increased awareness and screening programs, resulting in earlier detection and improved survival rates. To meet the changing demands of patients, ongoing research and development activities are focused on developing targeted medicines, immunotherapies, and personalized medicine. Thus, owing to the increase in diagnosis of cancer the market is expected to drive over the forecast period.
The Development of Novel Therapeutic Options will Drive the Market Growth
The use of novel therapeutic options is expected to dominate the market. Due to the factors such as resistance developed by conventional therapies such as chemotherapy, and advancements in gene therapies. For instance, in April 2023, researchers at the University Hospital Bonn (UKB) identified a potentially innovative therapeutic approach for people with cisplatin-resistant in testicular cancer. The researchers discovered the NAE1 gene as the key regulator of cisplatin resistance in testicular cancer cells using CRISPR gene scissors.
The NAE1 inhibitor MLN4924 not only restored cisplatin's efficacy but also increased tumor cell killing. These findings raise the potential of new and more effective medicines to address cisplatin resistance in patients with testicular cancer, potentially enhancing treatment outcomes. Thus, owing to the advancements in treatment option for testicular cancer is expected to drive the market over the foreseeable future.
The Side Effects Associated For Testicular Cancer Treatment Will Hamper the Growth of the Market
The testicular cancer market is expected to be hamper owing to the factors such as side effects from cancer drugs and lack of early detection. While chemotherapy is effective, it can cause fatigue, nausea, vomiting, numbness, tingling, hearing loss, and ringing in the ears, as well as an increased risk of serious infections.
For instance, the drug bleomycin has been associated to cause serious lung inflammation, prompting immediate notification of symptoms to healthcare providers. Furthermore, people getting treatment for testicular cancer are prone to develop blood clots.
Segment Analysis
The global testicular cancer market is segmented based on types, stages, drug class, treatment, distribution channel, and region.
Owing to its Better Effectiveness, the Surgery Segment Accounted for Approximately 34.6% of the Testicular Cancer Market Share
The surgery segment is poised to dominate the testicular cancer market as it remains a first-line and preferred medical treatment for testicular cancer owing to its effectiveness, advancements in technologies, and better cure for testicular cancer. Surgery is the mainstay treatment for this cancer that involves the removal of lymph nodes in the area behind the abdomen lining called the retroperitoneum.
Also, radical inguinal orchiectomy surgery is performed to treat both seminoma and non-seminoma testicular cancers. Furthermore, advancement in technologies such as minimally invasive procedures is driving market growth.
For instance, Mount Sinai Hospital performed robot-assisted retroperitoneal lymph node dissection (R-RPLND) surgery. R-RPLND is a new surgical treatment for testicular cancer that is less invasive than open RPLND. The surgery involves making five small incisions to resect tumors in the retroperitoneum, which allows patients to recover faster. Thus, owing to the advancement in surgery treatment the segment is expected to dominate over the forecast period.
Geographical Penetration
North America Accounted for Approximately 40.7% of the Market Share in 2022, Owing to the Increase in the Number of Clinical Trails
North America, particularly the United States, dominates the global testicular cancer market due to its presence of established market players, along with increasing funding by the companies for the development of novel treatment approaches. Furthermore, the increasing number of clinical trials led to novel treatments for better patient outcomes.
For instance, UNC Lineberger Comprehensive Cancer Center in collaboration with University Cancer Research Fund at Lineberger Comprehensive Cancer Center is conducting a clinical trial began in 2022. This is a phase 2 clinical trial for adults with Nonseminomatous Germ Cell Tumours (NSGCT). The objective of this research is to establish a repository and look for the presence of changed T cells in the subjects' plasma or tumors. The biospecimens collected, which include tumor tissue, blood, and modified T cells, will be utilized to learn more about the existence and longevity of modified T cells in the body and tumor.
Furthermore, the study attempts to boost future cancer treatment choices by merging two separate ways of fighting disease: antibodies and T cells. The study is based on the safety and efficacy data from prior ATLCAR dosing trials. CD30 is a treatment that combines autologous T lymphocyte chimeric antigen receptor cells that are specific for the CD30 antigen with patients and the estimated completion of a trial is in December 2026.
Competitive Landscape
The major global players in the testicular cancer market include Pfizer Inc., Fresenius Kabi AG, Abbott, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Xediton Pharmaceuticals, Accord Healthcare Limited, Baxter Healthcare Corporation, Sandoz International GmbH and Hikma Pharmaceuticals PLC. among others.
COVID-19 Impact Analysis
The COVID-19 pandemic can have an impact on the testicular cancer market, particularly in the context of male reproductive health. Because males are more susceptible to COVID-19, researchers have looked into whether the virus impacts testicular function and whether it is present in seminal fluid. Following COVID-19 infection, studies have shown changes in semen parameters, alterations in the hormonal axis, and gamete dysfunction.
The identification of viral proteins in testicular tissue after death adds support to the possibility of testicular COVID-related harm. Furthermore, infection with SARS-CoV-2 could affect pro-inflammatory mediators, potentially causing testicular injury and raising the risk of infertility. These findings indicate the importance of more research on the long-term effects of COVID-19 on male reproductive health and its potential impact on the testicular cancer market.
Russia Ukraine Conflict Analysis
The Russia-Ukraine conflict is having impact on the global testicular cancer market. The conflict has decreased access to healthcare services in Ukraine, making it harder for testicular cancer patients to receive critical treatment. The increased financial load on patients as a result of treatment costs and economic instability has further hampered access to care. Delayed diagnosis and treatment have also been noted as people are unwilling to seek medical help during the conflict.
These obstacles have had a detrimental impact on the worldwide testicular cancer market, producing slower growth than expected. However, there is potential for development, such as a greater emphasis on creating more effective treatment options and improving testicular cancer awareness in Ukraine. As the war ends and healthcare access improves, the market is projected to rebound. Nonetheless, the conflict's impact on the market is still enormous, necessitating continual efforts to handle the problems and opportunities it brings.
By Types
• Germ Cell Tumors
o Seminomas
• Classical Seminoma
• Spermatocytic Seminoma
o Non-Seminomas
• Embryonal Carcinoma
• Yolk Sac Carcinoma
• Choriocarcinoma
• Teratoma
• Stromal Tumors
o Leydig Cell Tumors
o Sertoli Cell Tumors
• Others
By Stages
• Stage 0
• Stage I
• Stage II
• Stage III
By Drug Class
• Alkylating Agent
• Topoisomerase II Inhibitor
• Glycopeptide Antibiotics
• Antimicrotubular Agents
• Others
By Treatment
• Surgery
• Radiation Therapy
• Chemotherapy
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On June 23, 2022, BioNTech SE stated that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) classification to BioNTech's fully owned product candidate BNT211 for the third- or later-line treatment of testicular germ cell tumors. BNT211 is a potential first-in-class therapeutic approach that combines two of the Company's proprietary drug products, an autologous chimeric antigen receptor (CAR) T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac).
• On June 2, 2023, the US Food and Drug Administration is collaborating with Chinese pharmaceutical company Qilu Pharmaceutical to increase supplies of the cancer medicine cisplatin, which is currently in low supply. Apotex, a Canadian pharmaceutical company, will temporarily provide the injectable drug in 50-milligram vials. Cisplatin has a cure rate of more than 90% when used to treat testicular cancer. It also treats malignancies of the bladder, cervix, ovary, lung, stomach, breast, and head and neck.
Why Purchase the Report?
• To visualize the global testicular cancer market segmentation based on type, stages, drug class, treatment, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of testicular cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global testicular cancer market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Stages
3.3. Snippet by Drug Class
3.4. Snippet by Treatment
3.5. Snippet by Distribution Channel
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Increasing Diagnosis of Testicular Cancer
4.1.1.2. The Development of Novel Therapeutic Options
4.1.2. Restraints
4.1.2.1. The Side Effects Associated with Testicular Cancer Treatment
4.1.3. Opportunity
4.1.3.1. Increasing Demand for Personalized Medicine
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Types
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Types
7.1.2. Market Attractiveness Index, By Types
7.2. Germ Cell Tumors*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.2.1. Seminomas
7.2.2.1.1. Classical Seminoma
7.2.2.1.2. Spermatocytic Seminoma
7.2.2.2. Non-Seminomas
7.2.2.2.1. Embryonal Carcinoma
7.2.2.2.2. Yolk Sac Carcinoma
7.2.2.2.3. Choriocarcinoma
7.2.2.2.4. Teratoma
7.3. Stromal Tumors
7.3.1. Leydig Cell Tumors
7.3.2. Sertoli Cell Tumors
7.4. Others
8. By Stages
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stages
8.1.2. Market Attractiveness Index, By Stages
8.2. Stage 0*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Stage I
8.4. Stage II
8.5. Stage III
9. By Drug Class
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Alkylating Agent*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Topoisomerase II Inhibitor
9.4. Glycopeptide Antibiotics
9.5. Antimicrotubular Agents
9.6. Others
10. By Treatment
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.1.2. Market Attractiveness Index, By Treatment
10.2. Surgery*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Radiation Therapy
10.4. Chemotherapy
10.5. Others
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Types
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stages
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Types
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stages
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. U.K.
12.3.8.3. France
12.3.8.4. Spain
12.3.8.5. Italy
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Types
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stages
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Types
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stages
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Types
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stages
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Pfizer Inc.*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Fresenius Kabi AG
14.3. Abbott
14.4. Teva Pharmaceutical Industries Ltd.
14.5. Eli Lilly and Company
14.6. Xediton Pharmaceuticals
14.7. Accord Healthcare Limited
14.8. Baxter Healthcare Corporation
14.9. Sandoz International GmbH
14.10. Hikma Pharmaceuticals PLC
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4.	Key Developments, Fresenius Kabi AG, Abbott, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Xediton Pharmaceuticals, Accord Healthcare Limited, Baxter Healthcare Corporation, Sandoz International GmbH, Hikma Pharmaceuticals PLC

표 목록 (Tables)

List of Tables Table 1 Global Testicular Cancer Market Value, By Types, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Testicular Cancer Market Value, By Stages, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Testicular Cancer Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Testicular Cancer Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Testicular Cancer Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Testicular Cancer Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Testicular Cancer Market Value, By Types, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Testicular Cancer Market Value, By Types, 2021-2030 (US$ Million)

Table 9 Global Testicular Cancer Market Value, By Stages, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Testicular Cancer Market Value, By Stages, 2021-2030 (US$ Million)

Table 11 Global Testicular Cancer Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Testicular Cancer Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 13 Global Testicular Cancer Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 14 Global Testicular Cancer Market Value, By Treatment, 2021-2030 (US$ Million)

Table 15 Global Testicular Cancer Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 16 Global Testicular Cancer Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 17 Global Testicular Cancer Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 18 Global Testicular Cancer Market Value, By Region, 2021-2030 (US$ Million)

Table 19 North America Testicular Cancer Market Value, By Types, 2021-2030 (US$ Million)

Table 20 North America Testicular Cancer Market Value, By Stages, 2021-2030 (US$ Million)

Table 21 North America Testicular Cancer Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 22 North America Testicular Cancer Market Value, By Treatment, 2021-2030 (US$ Million)

Table 23 North America Testicular Cancer Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 North America Testicular Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 25 South America Testicular Cancer Market Value, By Types, 2021-2030 (US$ Million)

Table 26 South America Testicular Cancer Market Value, By Stages, 2021-2030 (US$ Million)

Table 27 South America Testicular Cancer Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 28 South America Testicular Cancer Market Value, By Treatment, 2021-2030 (US$ Million)

Table 29 South America Testicular Cancer Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 South America Testicular Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Europe Testicular Cancer Market Value, By Types, 2021-2030 (US$ Million)

Table 32 Europe Testicular Cancer Market Value, By Stages, 2021-2030 (US$ Million)

Table 33 Europe Testicular Cancer Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 34 Europe Testicular Cancer Market Value, By Treatment, 2021-2030 (US$ Million)

Table 35 Europe Testicular Cancer Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 36 Europe Testicular Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 37 Asia-Pacific Testicular Cancer Market Value, By Types, 2021-2030 (US$ Million)

Table 38 Asia-Pacific Testicular Cancer Market Value, By Stages, 2021-2030 (US$ Million)

Table 39 Asia-Pacific Testicular Cancer Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 40 Asia-Pacific Testicular Cancer Market Value, By Treatment, 2021-2030 (US$ Million)

Table 41 Asia-Pacific Testicular Cancer Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 42 Asia-Pacific Testicular Cancer Market Value, By Country, 2021-2030 (US$ Million)

Table 43 Middle East & Africa Testicular Cancer Market Value, By Types, 2021-2030 (US$ Million)

Table 44 Middle East & Africa Testicular Cancer Market Value, By Stages, 2021-2030 (US$ Million)

Table 45 Middle East & Africa Testicular Cancer Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 46 Middle East & Africa Testicular Cancer Market Value, By Treatment, 2021-2030 (US$ Million)

Table 47 Middle East & Africa Testicular Cancer Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 48 Pfizer Inc.: Overview

Table 49 Pfizer Inc.: Product Portfolio

Table 50 Pfizer Inc.: Key Developments

Table 51 Fresenius Kabi AG: Overview

Table 52 Fresenius Kabi AG: Product Portfolio

Table 53 Fresenius Kabi AG: Key Developments

Table 54 Abbott: Overview

Table 55 Abbott: Product Portfolio

Table 56 Abbott: Key Developments

Table 57 Teva Pharmaceutical Industries Ltd.: Overview

Table 58 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 59 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 60 Eli Lilly and Company: Overview

Table 61 Eli Lilly and Company: Product Portfolio

Table 62 Eli Lilly and Company: Key Developments

Table 63 Xediton Pharmaceuticals: Overview

Table 64 Xediton Pharmaceuticals: Product Portfolio

Table 65 Xediton Pharmaceuticals: Key Developments

Table 66 Accord Healthcare Limited: Overview

Table 67 Accord Healthcare Limited: Product Portfolio

Table 68 Accord Healthcare Limited: Key Developments

Table 69 Baxter Healthcare Corporation: Overview

Table 70 Baxter Healthcare Corporation: Product Portfolio

Table 71 Baxter Healthcare Corporation: Key Developments

Table 72 Sandoz International GmbH: Overview

Table 73 Sandoz International GmbH: Product Portfolio

Table 74 Sandoz International GmbH: Key Developments

Table 75 Hikma Pharmaceuticals PLC: Overview

Table 76 Hikma Pharmaceuticals PLC: Product Portfolio

Table 77 Hikma Pharmaceuticals PLC: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 2 Global Testicular Cancer Market Share, By Types, 2022 & 2030 (%)

Figure 3 Global Testicular Cancer Market Share, By Stages, 2022 & 2030 (%)

Figure 4 Global Testicular Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 5 Global Testicular Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 6 Global Testicular Cancer Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 7 Global Testicular Cancer Market Share, By Region, 2022 & 2030 (%)

Figure 8 Global Testicular Cancer Market Y-o-Y Growth, By Types, 2022-2030 (%)

Figure 9 Germ Cell Tumors Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 10 Stromal Tumors Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 11 Others Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 12 Global Testicular Cancer Market Y-o-Y Growth, By Stages, 2022-2030 (%)

Figure 13 Stage 0 Stages in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 14 Stage I Stages in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 15 Stage II Stages in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 16 Stage III Stages in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 17 Global Testicular Cancer Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 18 Alkylating Agent Drug Class in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 19 Topoisomerase II Inhibitor Drug Class in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 20 Glycopeptide Antibiotics Drug Class in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 21 Antimicrotubular Agents Drug Class in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 22 Others Drug Class in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 23 Global Testicular Cancer Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 24 Surgery Treatment in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 25 Radiation Therapy Treatment in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 26 Chemotherapy Treatment in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 27 Others Treatment in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 28 Global Testicular Cancer Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 29 Hospital Pharmacies Distribution Channel in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 30 Retail Pharmacies Distribution Channel in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 31 Online Pharmacies Distribution Channel in Global Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 32 Global Testicular Cancer Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 33 North America Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 34 Asia-Pacific Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 35 Europe Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 36 South America Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 37 Middle East and Africa Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 38 North America Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 39 North America Testicular Cancer Market Share, By Types, 2022 & 2030 (%)

Figure 40 North America Testicular Cancer Market Share, By Stages, 2022 & 2030 (%)

Figure 41 North America Testicular Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 42 North America Testicular Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 43 North America Testicular Cancer Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 44 North America Testicular Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 45 South America Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 46 South America Testicular Cancer Market Share, By Types, 2022 & 2030 (%)

Figure 47 South America Testicular Cancer Market Share, By Stages, 2022 & 2030 (%)

Figure 48 South America Testicular Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 49 South America Testicular Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 50 South America Testicular Cancer Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 51 South America Testicular Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 52 Europe Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 53 Europe Testicular Cancer Market Share, By Types, 2022 & 2030 (%)

Figure 54 Europe Testicular Cancer Market Share, By Stages, 2022 & 2030 (%)

Figure 55 Europe Testicular Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 56 Europe Testicular Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 57 Europe Testicular Cancer Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 58 Europe Testicular Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 59 Asia-Pacific Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 60 Asia-Pacific Testicular Cancer Market Share, By Types, 2022 & 2030 (%)

Figure 61 Asia-Pacific Testicular Cancer Market Share, By Stages, 2022 & 2030 (%)

Figure 62 Asia-Pacific Testicular Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 63 Asia-Pacific Testicular Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 64 Asia-Pacific Testicular Cancer Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 65 Asia-Pacific Testicular Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 66 Middle East & Africa Testicular Cancer Market Value, 2021-2030 (US$ Million)

Figure 67 Middle East & Africa Testicular Cancer Market Share, By Types, 2022 & 2030 (%)

Figure 68 Middle East & Africa Testicular Cancer Market Share, By Stages, 2022 & 2030 (%)

Figure 69 Middle East & Africa Testicular Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 70 Middle East & Africa Testicular Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 71 Middle East & Africa Testicular Cancer Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 72 Pfizer Inc.: Financials

Figure 73 Fresenius Kabi AG: Financials

Figure 74 Abbott: Financials

Figure 75 Teva Pharmaceutical Industries Ltd.: Financials

Figure 76 Eli Lilly and Company: Financials

Figure 77 Xediton Pharmaceuticals: Financials

Figure 78 Accord Healthcare Limited: Financials

Figure 79 Baxter Healthcare Corporation: Financials

Figure 80 Sandoz International GmbH: Financials

Figure 81 Hikma Pharmaceuticals PLC: Financials

세계 고환암 시장 – 2023-2030

Global Testicular Cancer Market - 2023-2030